Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03703050
Title Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) (NIVO-ALCL)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Gustave Roussy, Cancer Campus, Grand Paris
Indications

anaplastic large cell lymphoma

Therapies

Nivolumab

Age Groups: adult | child | senior
Covered Countries FRA

Facility Status City State Zip Country Details
Rigshospitalet Recruiting Copenhagen Denmark Details
Gustave Roussy Recruiting Villejuif Val De Marne 94805 France Details
CHU Bordeaux Hopital Pellegrin Recruiting Bordeaux 33076 France Details
Centre Léon Berard Lyon Recruiting Lyon 69008 France Details
Hopital Saint Louis Withdrawn Paris 75010 France Details
CHU Toulouse Hopital des enfants Recruiting Toulouse 31059 France Details
IUC Toulouse Recruiting Toulouse 31059 France Details
CHU de nancy Recruiting Vandœuvre-lès-Nancy 54500 France Details
Princess Maxima center Not yet recruiting Utrecht Netherlands Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field